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Abstract 
Objective Little is known about how women with isolated GnRH deficiency cope with their 
condition. This study aimed to examine the health and informational needs of women with 
congenital hypogonadotropic hypogonadism (CHH) and evaluate if their experiences differ from 
women with more common forms of infertility.  
 
Design Cross-sectional, multiple methods study using web-based data collection to reach 
dispersed rare disease patients. 
 
Methods A community-based participatory research framework was employed to develop an 
online survey and collect quantitative and qualitative data. Adult women diagnosed with CHH 
who had received at least one year of hormonal treatment completed the Morisky Medication 
Adherence Scale, Revised Illness Perception Questionnaire and Zung Self-Rating Depression 
Scale. Information on healthcare experiences, treatment outcomes and patient-reported 
challenges were also collected. 
 
Results Women (n=55) were often diagnosed late (20.7±7.4, range: 10-48 years) and 16/20 
patients receiving fertility treatment conceived. Poor adherence was frequently observed (34/55) 
while more than half (27/49) reported a gap in treatment exceeding a year. Low adherence 
correlated with depressive symptoms (r=0.3, p>0.05). Negative illness perceptions were 
pervasive and 30/55 exhibited some depressive symptoms - significantly greater than women 
with common female factor infertility (p<0.01). Symptoms were underappreciated by providers 
as only 15 of 55 patients had discussions about psychological services. Women identified 
isolation, need for information and finding expert care as challenges to living with CHH.  
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Conclusions Despite being a treatable form of female infertility, the presumable availability of 
treatment does not necessarily ensure adequate quality of life for women with isolated GnRH 
deficiency. 
 
 
Introduction 
Infertility affects ~10-15% of women globally, and is a significant health concern 1. Sometimes 
referred to as the pilot light of reproduction, gonadotropin-releasing hormone (GnRH) secretion 
is essential for developing and maintaining reproductive capacity 2. Acquired GnRH deficiency 
(i.e. hypothalamic amenorrhea) is a common cause of secondary amenorrhea that is reversible 
3. More severe forms of GnRH deficiency, such as congenital hypogonadotrophic hypogonadism 
(CHH), are much less common. However, CHH is responsive to hormonal therapy and is a 
treatable form of infertility that does not necessarily require invasive assisted reproduction 
techniques 4. 
 
In its most severe form, CHH presents as a complete absence of puberty with undetectable 
serum gonadotropins and hypogonadal sex steroid levels. Clinical presentation is variable: 
some patients display partial puberty 5, there is a wide range of associated phenotypes (e.g. 
absent sense of smell, skeletal anomalies, mirror movements, renal agenesis) and cases of 
reversal have been reported 6. Similarly, genetic etiology is heterogeneous with more than 25 
genes having been identified in relation to CHH and the genetic architecture can sometimes be 
complex as evidenced by oligogenicity 4. CHH is rare (1:4,000-10,000) and there is a striking 
sexual discordance. Combining three large patient cohorts from the United States (n=250) 7, 
United Kingdom (n=215) 8 and France (n=334) 9 reveals the male to female ratio to be 3.6 to 1. 
Yet, unlike many other rare disorders, effective treatments are available. Hormone replacement 
in the form of low dose oestradiol (titrated over time) is the standard treatment for younger 
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hypogonadal women to induce secondary sexual characteristics and menses 4. Combined 
gonadotrophin therapy or physiologic treatment with pulsatile GnRH are equally effective for 
inducing fertility in the vast majority of cases 10.  
 
Compared to fertile counterparts, women with infertility have higher levels of stress, anxiety, and 
depression all of which can erode quality of life 11. However, little is known about the 
experiences of women with CHH and how they cope with their condition. There is a body of 
literature on quality of life issues in women with primary infertility (i.e. Turner syndrome, TS) 12. 
However, differences in terms of timing of diagnosis, phenotype, and fertility potential preclude 
extending findings from women with a hypogonadotrophic cause of infertility (TS) to those with a 
hypogonadotrophic etiology (CHH). Notably, conducting research in rare disease patients is 
challenged by the fact that these patients are dispersed and difficult to reach. Therefore, the 
purpose of this study was to partner with patients and use web-based data collection to reach 
women with CHH to conduct a needs assessment to identify targets for developing more 
patient-centered approaches to care for these endocrine patients.  
 
Subjects and methods 
Design and subjects 
This cross-sectional needs assessment employed multiple methods within a community-based 
participatory research framework 13. We engaged patient community leaders in developing 
content and validating the online survey as well as for recruitment. Patients were identified via 
patient-oriented social media sites (i.e. Facebook, Rareconnect.org) and the international 
network studying GnRH deficiency (COST Action BM1105, www.gnrhdeficiency.eu) over a 14-
month period (October 2014-December 2015). CHH was defined as previously reported 5 and 
diagnosis was confirmed in a 40% random sample of respondents as described 14. Adult women 
(18+ years) with CHH who had been on hormonal treatment for at least one year were included 
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in the analysis. The project was reviewed and approved by the local ethics committee and all 
participants provided opt-in electronic consent.  
 
Needs assessment survey 
We co-constructed an online survey with patients including items on patient demographics, 
health literacy 15, medical history, healthcare interactions, sexuality, as well as several validated 
questionnaires. The selection of questionnaires was based on their relevance, validity and 
widespread use that facilitates comparison with particular patient populations of interest (i.e. 
women with infertility, and men with CHH and patients with rare endocrine disorders and chronic 
conditions). The Morisky Medication Adherence Scale (MMAS) is an 8-item instrument that 
assesses medication taking behavior to determine low, medium or high adherence 16-18. The 
Zung Self-Rating Depression Scale (SDS) is a widely-used, validated 20-item instrument 
quantifying the severity of affective, somatic, psychomotor, and psychological depressive 
symptoms 19, 20. The Illness Perception Questionnaire - Revised (IPQ-R) includes 38 statements 
to asses emotional and cognitive representations of illness spanning 7 dimensions: timeline 
acute/chronic (beliefs about the chronic nature of the condition), timeline cyclical (beliefs 
regarding the cyclical nature of the condition), consequences (negative consequences of the 
disease), personal control (perceived personal controllability of the disease), treatment control 
(perceived treatment controllability of the disease), emotional representations (the emotional 
responses generated by the illness), and illness coherence (personal understanding of the 
disease) 21. Additionally, patients had the opportunity to provide a free text response identifying 
what they perceive to be the most challenging aspects of living with CHH.  
 
Reference populations 
To provide context for the depressive symptoms in women with CHH, SDS scores were 
compared to: a) men with CHH (n=101) 22, b) women seeking assisted fertility treatment (n=872) 
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11 and c) community based rates in a healthy, non-psychiatric population (n=292) who 
completed the SDS monthly over the course of one full year 23. Because there are no normative 
scores for the IPQ-R for the general population (i.e. healthy adults), comparisons were made to 
patients with acute or chronic pain 24, men with CHH 22, and patients with acromegaly 24 to 
provide a clinical context for these data. Age at CHH diagnosis was compared to a population-
based sample for age of menarche 25. 
 
Analysis 
Descriptive statistics were used to present survey data. Comparisons between groups were 
performed using Student’s t-test or Mann-Whitney rank sum test as appropriate. Categorical 
values were compared using Chi-square test while Pearson product-moment correlations were 
performed to assess the associations between survey data. IPQ-R subscales were compared 
across the CHH and reference groups using ANOVA with Bonferroni post-hoc correction for 
multiple comparisons. Z-Scores were used to assess differences in the proportion of patients 
exhibiting depressive symptoms compared to community base rates. Survey data were 
analyzed using PASW Statistics version 17.0.2 (SPSS Inc., Chicago, IL). All data are presented 
as mean ± SD unless otherwise noted and a p ≤ 0.05 was considered statistically significant. 
Open-ended responses were analyzed using NVivo11 (QSR International PSY Ltd., Melbourne 
Australia). Deductive thematic analysis (deductive coding) was conducted by two independent 
investigators (SD:AD). Meaningful units were coded. These codes were sorted into categories 
and themes in an iterative process and consensus was achieved by discussion. The most 
frequent themes were given particular emphasis 26. 
 
Results 
The web-based survey was online for 14-months during which time 68 women responded. After 
removing incomplete survey responses and those not meeting inclusion criteria, 55 surveys 
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were included for analysis. Given the rarity of women with CHH 7-9, it appears that the 
combination of community partnerships and social media recruitment were effective for reaching 
these dispersed patients 14. Patient sociodemographic characteristics are depicted in Table 1. 
The women ranged in age from 18-68 years (mean 35±10, median 34), were well-educated 
(44/55, university or higher) with adequate health literacy and the majority of women were 
employed (41/55). 
 
Given that menarche is an important single-event signpost of puberty and that 90% of CHH 
women present with primary amenorrhea 5, earlier diagnosis and treated would be expected 
compared to male counterparts who lack such a hallmark. However, we found no such pattern 
(females: n=55; 95% CI: 18.7-22.7, males: n=101; 17.6-20.2 yrs; p=0.16) 22. The women were 
diagnosed between 10-48 years of age (Figure 1A), and more than half (n=32) had received 
any meaningful treatment prior to age 18 (95% CI: 17.2-20.6 yrs). Nearly two-thirds (34/55) of 
survey respondents had been seen at a specialized academic medical center (Table 2). Twenty 
women underwent fertility-inducing treatment, two-thirds (13/20) of whom at an academic 
medical center and the vast majority (16/20) successfully conceived, consistent with rates 
previously reported 27, 28, and in line with male CHH counterparts (95% CI: 60-85%) 29. In total, 
nearly half (25/55) of women had undergone genetic testing yet significantly fewer (11/55, 
p<0.005) received genetic counseling. Among surveyed patients, women receiving fertility-
inducing treatment were not more likely to have genetic testing (12/20, p=0.10), or counseling 
(5/20, p=0.48) compared to the larger group.  
 
All respondents included in the analysis had been on treatment for at least one year. Women 
completed the MMAS to assess adherence behavior (Table 2) and provided self-reported 
longest duration off treatment (Fig 1B). Notably, MMAS scores indicated low adherence in 
nearly two thirds (34/55) of women. Lifetime duration of treatment was weakly correlated with 
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MMAS (r=0.29, p<0.05). Only 11/49 reported never having a lapse in treatment – a proportion 
similar to those exhibiting the highest level of adherence on the MMAS (Table 1). However, 
more than half (27/49) reported long gaps in treatment (i.e. 12 months or longer). Similarly, 
18/43 claimed to have gone 2 years or longer without seeing a healthcare provider (data not 
shown).  
 
Across IPQ-R dimensions, women and men had comparable perceptions of their CHH with 
scores indicating significant emotional impact and negative consequences 22 (Table 3). These 
findings extend the findings of a small qualitative study including interviews with 5 women with 
CHH 30. Women with CHH perceived more negative consequences of their illness compared to 
both patients with acute pain and patients with acromegaly (both p<0.01) yet less than patients 
with chronic pain. The negative emotional impact of CHH was larger than in patients with 
acromegaly (p<0.01) but not different from patients with acute or chronic pain. Both negative 
consequences and emotional impact were modestly correlated with poorer medication 
adherence (r=0.298 and r=0.33 respectively, both p<0.05). Furthermore, females with CHH 
perceived less personal control over their illness than patients with acute pain (p<0.01), but did 
not differ from patients with chronic pain or acromegaly. In terms of treatment control, females 
with CHH perceived less treatment control than patients with acute pain or acromegaly (both 
p<0.01), but more treatment control than patients with chronic pain (p=0.01). Lastly, women with 
CHH exhibited the highest score on illness coherence compared to patients with acute or 
chronic pain (both p<0.01). This better understanding of their illness could be related to the 
congenital nature of CHH.  
 
More than half of women (30/55) exhibited some depressive symptoms. This is significantly 
increased compared to the 9% observed in a community a dwelling non-psychiatric population 
(p<0.001) 23 yet similar to their male CHH counterparts (64/100, p=N.S.) 22. Compared to those 
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presenting with more common female infertility (14.7% of 872 women) 11, women with CHH 
were more likely to exhibit depressive symptoms (p<0.01) and this relationship persisted when 
we limited the analysis to only those patients (25.6% of 193 women) with female factor infertility 
(p<0.01). In total, 14/55 of women with CHH exhibited mild depressive symptoms, 9/55 had 
moderated symptoms similar to the type of depression treated in an ambulatory setting while 
7/55 had severe depressive symptoms akin to major depressive disorder. We found depressive 
symptoms were moderately correlated with poorer medication adherence (r=0.3, p<0.05) 
consistent with prior studies in patients with chronic diseases 31. Depressive symptoms were 
also correlated with illness perception dimensions. We observed a strong correlation between 
depressive symptoms and negative emotional impact of CHH (r=0.6, p<0.0001), a moderate 
relationship with consequences (r=0.42, p<0.01) and a weak association with illness coherence 
– how one makes sense of their condition (r=0.35, p<0.01).  
 
Importantly, the increased depressive symptoms appear to be underappreciated as only 15 
women stated that their provider had discussed or provided a referral for psychological 
counseling. Half of the patients (28/55) perceived that their healthcare provider well-understood 
the medical aspects of their GnRH deficiency yet significantly fewer felt that their provider 
understood how patients feel about living with CHH (14/55, p<0.01). Women with CHH were 
more likely than their male counterparts to have been in a relationship and sexually active (both, 
p<0.05) 32. Despite this, nearly all women (51/55) cited issues of body image concerns, with 
(44/55) reporting feelings of shame or embarrassment about their body, and over half (32/55) 
found intimate relationships difficult and had experienced teasing or ridicule about their lack of 
development (31/55).  
 
Qualitative data were also collected as part of the survey. Patients were asked to describe the 
most challenging aspect of living with CHH and approximately two-thirds (36/55) responded. 
Page 10 of 23
11 
 
Responses were coded and the 61 topics thematically clustered in three categories: i) isolation 
and insecurity (n=24), ii) need for information and support (n=24), and iii) delayed diagnosis and 
finding expert care (n=13). A table with representative quotes is provided in the online 
supplemental data. We also asked patients where they sought information about their condition. 
Nearly all women (52/55) reported that they found information about their condition on the 
internet, 46/55 via online community and social media (i.e. Facebook, Rareconnect.org), and 
44/55 were informed by healthcare professionals. Despite high education and health literacy 
levels, approximately half (27/55) sought information from the medical literature. Patients rated 
healthcare professionals as the most important source of information followed by online 
community and the internet. Ratings of importance were not statistically significant between 
these sources (p=0.13). 
 
Discussion 
We found that women with CHH are often diagnosed late and experience significant physical, 
social and psychological consequences in relation to their condition. These findings have 
implications for developing more patient-centered approaches to care for these women. This 
cross-sectional study of 55 women is perhaps the most robust portrayal of this patient 
population to date. Data on women with CHH are scant with only a handful of single-center 
studies reporting on very small samples (i.e. n<15). Additionally, patients were involved in 
developing the study - this strengthens our confidence that the identified targets for improving 
care are aspects that matter to patients.  
 
Some aspects of this study may limit the ultimate transferability of the findings to all women with 
CHH. First, these patients were well-educated with high levels of health literacy. Second, the 
inherent Anglophone bias should engender caution in considering cultural equivalence. Third, 
given the sample size, we may be underpowered in some of our analyses. Indeed, difficulty in 
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recruiting adequate numbers of patients with rare diseases is widely acknowledged.  This 
challenge informed our strategy of using the internet and patient-oriented social media to reach 
these dispersed patients, which we acknowledge as a potential source of sampling bias. Finally, 
self-report nature of the instruments employed has its own limitations, albeit our goal was to 
better understand patient perspectives to identify unmet needs as an initial step in developing 
more patient-centered approaches to care. 
 
Data on the age of diagnosis in CHH women comprises a single article (n=5; mean: 23±9, 
range: 12-35, median 21 yrs) 30 along with some unpublished historic data (females: n=38; 
mean: 18.2±5, range: 10-53 yrs) 33. We found women with CHH are often diagnosed quite late 
and only 58% had received treatment prior to age 18. It is well-established that later induction of 
puberty for adolescent girls with Turner syndrome (TS) is associated with poor self-esteem, 
difficult social adjustment and diminished sex life 34, 35. Further, late diagnosis (and initiation of 
treatment) negatively impacts psychosexual development in men with CHH 32. Thus, greater 
attention to earlier detection and timely initiation of sex steroid therapy seems warranted.  
 
The vast majority (16 of 20) of women who underwent fertility treatment were able to conceive, 
in line with published literature 27, 28. Notably, relatively few (11/55) women had received genetic 
counseling. This is surprising given that the American College of Medical Genetics considers 
abnormal pubertal timing a clinical presentation requiring referral to a medical genetics 
professional (i.e. genetic counselor) 36. Further, both the European Society of Human Genetics 
and the European Society of Human Reproduction and Embryology consider genetic counseling 
necessary when genetic factors are related to the cause of infertility 37. However, in our cohort, 
women receiving fertility-inducing treatment were no more likely to have genetic testing or 
counseling. These data suggest either lack of awareness of the importance of genetic 
counseling for these patients, or may reflect inadequate access to specialists with sufficient 
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understanding of the sometimes complex genetics of CHH 38. Improved access to genetic 
counseling appears to be a relevant target for enhancing patient care. 
 
Long term adherence to treatment was problematic as more than half of women had a gap in 
care of a year or longer. Without treatment, these women rapidly become hypogonadal, with 
deleterious impact on mood, well-being, sex life, and bone health. A Finnish cohort of 24 men 
and 9 women found patients with the longest gaps in treatment exhibited the most impaired 
bone density 39. Additionally, risk for osteopenia/osteoporosis may be further compounded by 
late diagnosis, as up to 90% of adult bone mass is accumulated during adolescence 40. Delays 
in diagnosis (and treatment initiation) could prolong estrogen deficiency thus impairing bone 
mineralization. These data highlight the importance of adequate hormone replacement and 
ongoing follow-up to monitor bone density and adherence as well as the role for a coordinated 
transition to adult services to facilitate continuity of care 4, 39, 41.  
 
Women had negative illness perceptions yet exhibited relatively high scores on illness 
coherence. Interestingly, CHH women who had received fertility treatment (and were able to 
conceive) had significantly lower ratings of negative consequences (p<0.05) and emotional 
impact (p<0.05) compared to those without children. While the sample is small, this may 
represent a psychological buffering effect of successful fertility treatment. We did not employ a 
formal health-related quality of life (HR-QoL) instrument in this study, yet the negative illness 
perceptions and increased depressive symptoms observed in women with CHH are consistent 
with impaired HR-QoL. A recent study of women with TS showed impaired HR-QoL compared 
to controls 35. Interestingly, the study included 21 women with other types of congenital 
hypogonadism (14 with CHH, 7 with 46XX gonadal dysgenesis) whose SF-36 scores were quite 
similar. A subset of these patients completed the Female Sexual Function Index revealing 
impaired sexual desire, arousal, lubrication, orgasm and global satisfaction compared to 
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controls 35. Similarly in our cohort, body image concerns were pervasive and the majority of 
women stated that intimate relationships were difficult. A recent study of young adults with CHH 
during transition found that few young women felt adequately informed about sexuality (2/7), 
intimate relationships (1/7), potential future fertility (1/7) or intercourse/potential discomfort with 
sex (0/7) 42. These current data underscore the need for appropriate anticipatory guidance on 
the topics of sexuality and intimate relationships.  
 
The qualitative data analysis suggests that women struggle with feelings of isolation and finding 
expert care. They frequently reported having used the internet and social media to learn about 
their condition and to find support from other patients 14. The Pew Foundation identified patients 
with a rare disease as ‘internet power-users’ 43, which aligns with our findings. We have 
previously shown that web-based modalities are used by and acceptable to patients with CHH 
14. This may present a novel avenue for reaching these dispersed patients, engaging them and 
promoting health and self-management. The Institute of Medicine defines patient-centered care 
as being guided by patient values and is both respectful of, and responsive to individual 
preferences, needs, and values 44. The Picker Principles of patient-centered care 45 provide a 
useful framework for developing more patient-centered approaches to care. Accordingly, we 
have charted the findings from the present study onto this framework along with suggested 
avenues for translating the results of this study into improved care for women with CHH (see 
supplementary file). 
 
In summary, this participatory, multiple methods needs assessment identifies that women with 
CHH frequently have lengthy gaps in treatment/care, perceive their condition to have a 
significant psychosocial impact on their life, and exhibit increased depressive symptoms. Care 
for these women could be improved by earlier diagnosis and timely initiation of treatment, 
greater access to genetic counseling, and providing accurate information about CHH (and 
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fertility treatment) as well as offering professional and peer-to-peer psychological support. The 
internet is effective for reaching and connecting dispersed patients and web-based platforms 
may hold promise for delivering patient-centered interventions to empower patients for improved 
self-management and adherence. 
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Figure Legends 
 
Figure 1. Age at CHH diagnosis and self-reported adherence to treatment. (A) Age at CHH 
diagnosis for 55 women ranged from 10-48 years. The mean age at menarche for Caucasian 
females is shown as a horizontal line and the shaded region depicts ± two standard 
deviations36. Only 11/55 of women were diagnosed by age 15. (B) Self-reported adherence to 
treatment (n=49). Approximately one-quarter of respondents reported never having a gap in 
treatment. In total, more than half (27/49) reported a gap in treatment of a year or longer. 
Similarly 20/46 women reported having a lapse in healthcare exceeding one year (data not 
shown). Age at diagnosis was moderately correlated with duration of gap in healthcare (r=0.56, 
p<0.001).  
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 Table 1. Sociodemographic information of women with CHH (n=55) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Age (years) n (%) 
   18-29  16 (29%) 
   30-39 25 (46%) 
   40-49  9 (16%) 
   50-59  4 (7%) 
   60+  1 (2%) 
Education  
   high school/vocational 10 (18%) 
   university 28 (51%) 
   post-graduate 16 (29%) 
   no response 1 (2%) 
Health literacy25  
   adequate literacy 45/55 (82%) 
   inadequate literacy 10/55 (18%) 
Employment  
   working full-time 32 (58%) 
   working part-time 9 (16%) 
   not working/unemployed 8 (15%) 
   retired 1 (2%) 
   student 5 (9%) 
Relationship status  
   married 21 (38%) 
   in a relationship 14 (25%) 
   single   9 (16%) 
   never been in a relationship 4 (7%) 
   divorced  7 (13%) 
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Table 2. Healthcare experiences of women with CHH (n=55) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Use of 
the 
©MMAS is protected by US copyright laws. Permission for use is required. A 
license agreement is available from: Donald E. Morisky, ScD, ScM, MSPH, 
Professor, 294 Lindura Ct., Las Vegas, NV 89138-4632.   
 
Medical history n (%) 
   seen at a specialized academic medical center 34 (62%) 
   genetic testing performed  25 (45%) 
   genetic counseling received 11 (20%) 
   sought psychological counseling 16 (29%) 
Healthcare interactions  
   provider understands medical aspects of CHH 28 (51%) 
   provider understands patient’s feelings of living with CHH 14 (25%) 
   provider discussed or gave referral for counseling 15 (27%) 
   experienced discrimination in the healthcare system  15 (27%) 
Treatment and adherence  
   duration of treatment: mean±SD (range, median) 16 ±10 yrs (1-42, 17) 
   MMAS low adherence 34 (62%) 
              medium adherence 12 (22%) 
              high adherence 9 (16%) 
Fertility outcomes  
   received fertility inducing treatment 20/55 (36%) 
   biologic children 16/20 (80%) 
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Table 3. Comparison of IPQ-R scores between female CHH patients and other patient groups  
 
 
IPQ-R 
CHH (women) 
n=55 
CHH (men) 
n=101 
acute pain 
n=35 
chronic pain 
n=63 
acromegaly 
n=81 
Timeline (acute/chronic) 27.2 (3.6) 26.7 (3) 13.4 (5)** 23.1 (4)** 22.9 (6)** 
Timeline (cyclical)   9.2 (3.9)   9.7 (4)   9.4 (3) 12.9 (4)** 10.1 (4) 
Consequences 20.0 (5.1) 21.3 (4) 14.2 (4)** 23.5 (4)** 16.9 (5)** 
Emotional representations 17.8 (6.2) 19.2 (6) 16.1 (4) 19.8 (4) 12.6 (4)** 
Personal control 19.6 (4.9) 19.9 (5) 22.9 (4)** 18.4 (4) 17.5 (5) 
Treatment control 16.1 (3.3) 15.5 (4) 19.4 (3)** 14.2 (3)* 18.1 (3)** 
Illness coherence 16.5 (4.7) 18.1 (4)   9.3 (3)** 13.4 (5)** 17.5 (3) 
 
Data are mean (SD), * p<0.05 compared with CHH (women), ** p<0.01 compared with CHH (women) 
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